Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mohsin Sarwar

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
JPMA. the Journal of the Pakistan Medical Association|January 27, 2018
Frequency of carrier screening and preventive orientation among first degree relatives of Thalassaemia patientsSeemab Hashim, Mohsin Sarwar, Armish Arsalan, et al.
British Journal of Pharmacology|May 31, 2016
The actions of relaxin on the human cardiovascular systemMohsin Sarwar, Xiao-Jun Du, Thomas B Dschietzig, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|May 9, 2023
Targeting the tumor microenvironment: Potential strategy for cancer therapeuticsQuratulain Babar, Ayesha Saeed, Tanveer A Tabish, et al.
Cureus|March 18, 2020
Morgagni-Larrey Hernia: A Possible Cause of Recurrent Lower Respiratory Tract InfectionsMuhammad Usman Hashmi, Kaleem Ullah, Ayesha Tariq, et al.
British Journal of Pharmacology|February 6, 2010
Ligand-directed signalling at beta-adrenoceptorsBronwyn A Evans, Masaaki Sato, Mohsin Sarwar, et al.
Cureus|August 25, 2018
Dual or Mono Antiplatelet Therapy for the Prevention of Ischemic Stroke: A Literature ReviewIbrar Anjum, Tooba Kashif, Munis M Ahmed, et al.
ACS Chemical Neuroscience|June 11, 2020
In the Loop: Extrastriatal Regulation of Spiny Projection Neurons by GPR52Daisy L Spark, Miaomiao Mao, Sherie Ma, et al.
Kidney International|January 17, 2014
Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosisBryna S Man Chow, Martina Kocan, Sanja Bosnyak, et al.
Scientific Reports|June 9, 2017
ML290 is a biased allosteric agonist at the relaxin receptor RXFP1Martina Kocan, Mohsin Sarwar, Sheng Y Ang, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
JPMA. the Journal of the Pakistan Medical Association|January 27, 2018
Frequency of carrier screening and preventive orientation among first degree relatives of Thalassaemia patientsSeemab Hashim, Mohsin Sarwar, Armish Arsalan, et al.
British Journal of Pharmacology|May 31, 2016
The actions of relaxin on the human cardiovascular systemMohsin Sarwar, Xiao-Jun Du, Thomas B Dschietzig, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|May 9, 2023
Targeting the tumor microenvironment: Potential strategy for cancer therapeuticsQuratulain Babar, Ayesha Saeed, Tanveer A Tabish, et al.
Cureus|March 18, 2020
Morgagni-Larrey Hernia: A Possible Cause of Recurrent Lower Respiratory Tract InfectionsMuhammad Usman Hashmi, Kaleem Ullah, Ayesha Tariq, et al.
British Journal of Pharmacology|February 6, 2010
Ligand-directed signalling at beta-adrenoceptorsBronwyn A Evans, Masaaki Sato, Mohsin Sarwar, et al.
Cureus|August 25, 2018
Dual or Mono Antiplatelet Therapy for the Prevention of Ischemic Stroke: A Literature ReviewIbrar Anjum, Tooba Kashif, Munis M Ahmed, et al.
ACS Chemical Neuroscience|June 11, 2020
In the Loop: Extrastriatal Regulation of Spiny Projection Neurons by GPR52Daisy L Spark, Miaomiao Mao, Sherie Ma, et al.
Kidney International|January 17, 2014
Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosisBryna S Man Chow, Martina Kocan, Sanja Bosnyak, et al.
Scientific Reports|June 9, 2017
ML290 is a biased allosteric agonist at the relaxin receptor RXFP1Martina Kocan, Mohsin Sarwar, Sheng Y Ang, et al.
Pageof 1